1 / 58

Dalla medicina tradizionale alla medicina dell ’ evidenza per giungere a quella personalizzata

Dalla medicina tradizionale alla medicina dell ’ evidenza per giungere a quella personalizzata. Loreto Gesualdo UOC Nefrologia, Dialisi e Trapianto Azienda Ospedaliero-Universitaria Policlinico Università degli Studi di Bari. EXPERIENCE BASED MEDICINE. Patient / Doctor Empathy

majed
Download Presentation

Dalla medicina tradizionale alla medicina dell ’ evidenza per giungere a quella personalizzata

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Dalla medicina tradizionale alla medicina dell’evidenza per giungere a quella personalizzata Loreto Gesualdo UOC Nefrologia, Dialisi e Trapianto Azienda Ospedaliero-Universitaria Policlinico Università degli Studi di Bari

  2. EXPERIENCE BASED MEDICINE Patient/DoctorEmpathy Case History Semiotics p ? Accuracy Reproducibility

  3. EXPERIENCE BASED MEDICINE Patient/DoctorEmpathy Case History Semiotics p ? Accuracy Reproducibility

  4. PMC, march 2011

  5. What Is Personalized Medicine? “Personalized Medicine” refers to the tailoring of medical treatment to the individuals into subpopulations that differ in their susceptibility to a particular disease or their response to a specific treatment. Preventive or therapeutic interventions can then be concentrated on those who will benefit, sparing expense and side effects for those who will not. PMC 2010

  6. Some examples…….

  7. >2100 2010 > 6800 papers

  8. 2010 2011 2012 >2100 >2900 >2500 >3300 > 11.000 papers

  9. The “Omics” Era Transcriptomics Genomics Proteomics Metabolomics

  10. Gene Structural and Comparative Genomics DNA Transcription Functional Genomics Transcriptomics (Gene Expression) RNA Translation Proteomics Protein Environment PTMs Metabolomics Biochemical Circuitry Phenotypes Systemic Biology Monarch butterfly The new lexicon of “…omics”

  11. SYSTEMS BIOLOGY NETWORK IN PUGLIA REGION DEB Systems Biology Proteomics DETO CNR CARSO Transcriptomics Genomics and Metabolomics

  12. RETE REGIONALEDI OMICA E BIOLOGIA DEI SISTEMI BIOBANCA E DATABASE CLINICO GENOMICA PROTEOMICA METABOLOMICA BIOLOGIA DEI SISTEMI

  13. “State-of-the-art” Core FacilitiesRenal Center

  14. Renal Disease (Clinical Phase) Renal Disease (Pre-clinical Phase) How can we improve our understanding and treatment of renal diseases?

  15. Typical Current Intervention Earliest Clinical Detection Baseline Risk Initiating Events Earliest Molecular Detection Tools Needed for Prediction and Personalized Care Monitor Progression Predict Events Inform Therapeutics Decision Support Tools: Predict/Diagnose Assess Risk Refine Assessment Cost 1/reversibility Disease Burden Time Baseline Risk Disease Initiation and Progression Preclinical Progression Dynamic Genomics: Gene Expression Proteomics Metabolomics Molecular Imaging Therapeutic Decision Support Stable Genomics: Single Nucleotide Polymorphisms (SNPs) Haplotype Mapping Gene Sequencing Sources of New Biomarkers:

  16. Prospective Health Care Participating Population Late Chronic Cost 1/reversibility Disease Burden Early Chronic Low Risk High Risk Time Personalized Health Plan Personal Lifestyle Plan Disease Management Risk Modification Risk Assessment and Decision Support Tools

  17. Toxicity (ADR) Non-Responders The Empirical strategy for Drug Therapy Patients with same diagnosis treated with the same medications Adverse Drug Reactions (ADRs) are the fourth leading cause of hospitalization, fifth leading cause of mortality in the USA

  18. Sensitive (toxicity) Resistant (poor resp.) Relationship between Drug Dose and Response High _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Toxicity Response _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Efficacy Low Low Drug Dose High

  19. Many factors influence drug delivery & response but inheritance can have a predominant effect ? Pharmaco- genetics E. Vessell, 1980s

  20. Microarray technology and pharmacogenomics

More Related